Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 1246
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Enzychem Lifesciences Corporation, a pharmaceutical company, focuses on the development of oral small molecule therapies for patients with unmet medical needs for oncology, metabolic diseases, and inflammatory diseases in South Korea. It is also developing potential therapies based on EC-18 technology platform to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, and acute radiation syndrome. The...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is overpriced on P/FCF.
Data is available to registered users only
Buy
Sell